<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>BELEODAQ (belinostat) for injection - for Healthcare Professionals (HCPs)</title>
    <meta name="description" content="In the next round against relapsed or refractory PTCL, fight on with BELEODAQ. It is an HDAC inhibitor available for relapsed/refractory PTCL.">
    <!-- Favicon -->
    <link rel="icon" href="https://beleodaq.com/hcp/wp-content/uploads/2019/05/cropped-favicon-Beleodaq-32x32.png" sizes="32x32">
    <!-- Google fonts -->
    <link rel="preconnect" href="https://fonts.gstatic.com">
    <link href="https://fonts.googleapis.com/css2?family=Open+Sans:wght@300;400;600;700;800&family=Raleway:wght@700&display=swap" rel="stylesheet">
    <!-- CSS Reset -->
    <link rel="stylesheet" href="css/reset.css">
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/dosing.css">
</head>
<body>
    <!-- Header -->
    <header class="header">
        <!-- Indications and Usage -->
        <div class="indications">
            <h5 class="indications__title">Indications and Usage</h5>
            <p class="indications__body copyright">BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon veriﬁcation and description of clinical beneﬁt in the conﬁrmatory trial.</p>
        </div>
        <!-- Navigation -->
        <nav class="nav">
            <!-- Logo -->
            <a class="nav__logo" href="index.html">
                <img src="https://beleodaq.com/hcp/wp-content/uploads/2019/04/logonew.png" alt="BELEODAQ® (belinostat) for injection: For injection in the treatment of relapsed or refractory PTCL">
            </a>
            <!-- Header Buttons -->
            <div class="nav__buttons">
                <!-- Site Buttons (redirecting to other parts of site) -->
                <ul class="site-buttons">
                    <li>
                        <a class="site-buttons__button p" href="#">
                            Important Safety Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button p"
                        href="#">
                           Prescribing Information
                        </a>
                    </li>
                    <li>
                        <a class="site-buttons__button button--orange p" href="#">
                           Patient Site
                        </a>
                    </li>
                </ul>
                <!-- Nav Links and Dropdown Menus -->
                <ul class="navlinks">
                    <li>
                        <a class="navlinks__link p" href="ptcl.html">PTCL <br>Overview</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">About <br>Beleodaq</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="about.html">BELIEF <br>Trial</a>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="efficacy.html"><br>Efficacy</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Study design
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Baseline Characteristics
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Response Rate
                                </a>
                             </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Duration of Response
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="safety.html">Safety & Tolerability</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Adverse Reactions
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Tolerability
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li class="active">
                        <a class="navlinks__link--active p" href="dosing.html">Dosing & Administration</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dosing Schedule
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Dose Modifications
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="access.html">Access & Resources</a>
                        <ul class="dropdown dropdown--hidden">
                            <li>
                                <a href="" class="dropdown__item p">
                                    STAR
                                </a>
                            </li>
                            <li>
                                <a href="" class="dropdown__item p">
                                    Resources
                                </a>
                            </li>
                        </ul>
                    </li>
                    <li>
                        <a class="navlinks__link p" href="#">Contact <br>Us</a>
                    </li>
                </ul>
            </div>
        </nav>
    </header>
    <!-- Main -->
    <main>
        <h2 class="primary">Just a Short, 30-Minute Intravenous Infusion</h2>
       
        <h3 class="secondary-variant">No recommended pretreatment is required<sup>1</sup></h3>

        <div class="timeline">
            <div class="timeline__item">
                <h4 class="primary semibold">Dosage</h4>
                <img src="assets/svg/dosing/iv.svg" alt="IV Bag" />
                <h4 class="light">The <span class="primary semibold">recommended dosage of BELEODAQ</span> is 1000 mg/m2</h4>
            </div>
            <div class="timeline__item">
                <img src="assets/svg/dosing/arrow.svg" alt="Next Arrow" />
            </div>
            <div class="timeline__item">
                <h4 class="primary semibold">Infusing Time</h4>
                <img src="assets/svg/dosing/watch.svg" alt="stop watch" />
                <h4 class="light">Short, 
                    infusion <span class="primary semibold">30-minute</span></h4>
            </div>
            <div class="timeline__item">
                <img src="assets/svg/dosing/arrow.svg" alt="Next Arrow" />
            </div>
            <div class="timeline__item">
                <h4 class="primary semibold">Dosing Schedule</h4>
                <img src="assets/svg/dosing/calendar.svg" alt="calendar" />
                <h4 class="light"><span class="primary semibold">5 days</span> on,<br>
                    <span class="primary semibold">16 days</span> off<sup>*</sup></h4>
            </div>
        </div>

        <p class="light">*Repeat every 21 days until disease progression or unacceptable toxicity.<sup>1</sup>
        </p>

        <h2 class="primary">
            Modify BELEODAQ Treatment by Adjusting Dosage as Needed<sup>1</sup>
        </h2>
        <h3 class="secondary-variant">Modifying the dosage may allow for the possibility of continued treatment in some patients<sup>1</sup></h3>
        <div class="toxicity">
            <div class="toxicity__item">
                <h3 class="secondary-variant">Dosage modifications for hematologic toxicities<sup>1</sup></h3>
                <ul>
                    <li>
                        <h4 class="light">
                        Base dosage adjustments for thrombocytopenia and neutropenia on the nadir (lowest value) for platelet and absolute neutrophil count (ANC) in the preceding cycle of therapy
                    </h4></li>
                    <li>
                        <h4 class="light">
                        ANC should be ≥100,000/μL, and the platelet count should be ≥50,000/μL prior to the start of each cycle and prior to resuming treatment following discontinuation because of toxicity
                        <ul>
                            <li>Resume subsequent treatment with BELEODAQ according to the guidelines described in the table to the right</li>
                            <li>Discontinue BELEODAQ in patients who have recurrent ANC nadirs &lt;50,000/μL and/or recurrent platelet count nadirs &lt;25,000/μL after 2 dosage reductions</li>
                        </ul>
                    </h4></li>
                </ul>
                <h3 class="secondary-variant">Preparation and administration precautions<sup>1</sup></h3>
                <ul>
                    <li>
                        <h4 class="light">
                        As with other potentially cytotoxic anticancer agents, exercise care in the handling and preparation of solutions prepared with BELEODAQ</h4></li>
                </ul>
            </div>
            <div class="toxicity__item">
                <h3 class="secondary-variant">Toxicity and dosage modification<sup>1</sup></h3>
                <div class="box darkest">
                    <div class="box__header">
                    <h4><span class="semibold">Platelet count</span> ≥ 25,000/μL and<br>
                        <span class="semibold">nadir ANC</span> ≥ 50,000/μL</h4>
                    </div>
                    <div class="box__content">
                        <h5>NO CHANGE</h5>
                    </div>
                </div>
                <div class="box darker">
                    <div class="box__header">
                    <h4><span class="semibold">Nadir ANC</span> &lt; 50,000/μL<br>
                        (any platelet count)</h4>
                    </div>
                    <div class="box__content">
                        <h5>DECREASE DOSAGE BY
                            <span class="jumbo">25%</span>
                            <span class="light">(750 mg/m2)</span></h5>
                    </div>
                </div>
                <div class="box">
                    <div class="box__header">
                    <h4><span class="semibold">Platelet count</span> &lt; 25,000/μL<br>
                        (any nadir ANC)</h4>
                    </div>
                    <div class="box__content">
                        <h5>DECREASE DOSAGE BY
                            <span class="jumbo">25%</span>
                            <span class="light">(750 mg/m2)</span></h5>
                    </div>
                </div>
            </div>
        </div>

        <div class="modifications">
            <h4 class="light">
                Toxicities must be NCI-CTCAE grade 2 or less prior to retreatment
            </h4>
            <div class="mod-item">
                <h4 class="secondary-variant">
                    Dosage modifications for nonhematologic toxicities<sup>1</sup>
                </h4>
                <div class="boxes">
                    <div class="box">
                        <div class="box__header">
                            <h4 class="light">Any CTCAE 
                                grade 3 or 4 AE<sup>*</sup></h4>
                        </div>
                        <div class="box__content">
                            <h5>DECREASE DOSAGE BY
                                <span class="jumbo">25%</span>
                                <span class="light">(750 mg/m2)</span></h5>
                        </div>
                    </div>
                    <div class="box">
                        <div class="box__header">
                            <h4 class="light">Recurrence of CTCAE 
                                grade 3 or 4 AE 
                                after 2 dosage reductions </h4>
                        </div>
                        <div class="box__content">
                            <h5>DISCONTINUE
                                <span class="jumbo">BELEODAQ</span>
                                </h5>
                        </div>
                    </div>
                </div>
                <p class="light"><sup>*</sup>For nausea, vomiting, and diarrhea, only dose modify if the duration is >7 days with supportive management.1</p>
            </div>
        </div>

        <div class="bounding_box">
            <div class="bb_item">
                <h4 class="primary">Dosage modifications for patients with reduced UGT1A1 activity<sup>1</sup>
                </h4>
                <div class="item__content">
                    <img src="assets/svg/dosing/down-iv.svg" alt="Down Arrow with IV Bag" />
                    <h4 class="light">Reduce the starting dose of BELEODAQ to <span class="primary semibold">750 mg/m2</span> in patients known to be homozygous for the UGT1A1*28 allele</h4>
                </div>
            </div>
            <div class="bb_item">
                <h4 class="secondary-variant">
                    Use in patients with renal impairment<sup>1</sup>
                </h4>
                <div class="item__content">
                    <img src="assets/svg/dosing/kidney.svg" alt="Kidney Illustration" />
                    <h4 class="light">BELEODAQ exposure <span class="secondary-variant semibold">is not altered in patients</span> with creatinine clearance (CrCl) >39 mL/min<br>
                        There are insufficient data to recommend a dose of BELEODAQ in patients with CrCl ≤39 mL/min
                     </h4>
                </div>
            </div>
        </div>
        <h4 class="secondary">Monitor complete blood counts at baseline and weekly<sup>1</sup><br>
            Perform serum chemistry tests, including renal and hepatic functions, prior to the start of the first dose of each cycle
            <sup>1</sup></h4>

        <div class="button-group">
            <a href="safety.html" class="button secondary">&larr; Safety & Tolerability</a>
            <a href="dosing2.html" class="button">Next &rarr;</a>
        </div>
    </main>
    <!-- ISI -->
    <footer id="footer">
        <section class="isi">
            <div>
                <h5 class="isi__header">Select Important Safety Information</h5>
                <p class="isi__body"><span class="isi__body--bold ">Warnings and Precautions</span>
                BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary.</p>
            </div>
            <a class="isi__button" href="#footer">
                See More <span>&uarr;</span>
            </a>
        </section>
        <section class="hidden">
            <h5 class="primary">Indications and Usage</h5>
            <ul>
                <li>
                    <p>BELEODAQ is a HDAC inhibitor indicated for the treatment of patients with R/R PTCL</p>
                </li>
                <li>
                    <p>This indication is approved under accelerated approval based on tumor response rate and DoR. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
                    </p>
                </li>
            </ul>

            <h5 class="primary">Warnings and Precautions</h5>
            <p><span class="semibold">Hematologic Toxicity:</span> BELEODAQ can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment and modify dosage as necessary.</p>
            <p><span class="semibold">Infections:</span> Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with BELEODAQ. Do not administer BELEODAQ to patients with an active infection. Patients with a history of extensive or intensive chemotherapy may be at a higher risk of life-threatening infections.</p>
            <p><span class="semibold">Hepatotoxicity:</span> BELEODAQ can cause fatal hepatotoxicity and liver function test abnormalities. Monitor liver function tests before treatment and before the start of each cycle. Interrupt or adjust dosage until recovery, or permanently discontinue BELEODAQ based on the severity of the hepatic toxicity.</p>
            <p><span class="semibold">Tumor Lysis Syndrome:</span> Tumor lysis syndrome has occurred in BELEODAQ-treated patients in the clinical trial of patients with relapsed or refractory PTCL. Monitor patients with advanced stage disease and/or high tumor burden, and take appropriate precautions.</p>
            <p><span class="semibold">Gastrointestinal Toxicity:</span> Nausea, vomiting, and diarrhea occur with BELEODAQ and may require the use of antiemetic and antidiarrheal medications.</p>
            <p><span class="semibold">Embryo-Fetal Toxicity:</span> BELEODAQ can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with BELEODAQ and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with BELEODAQ and for 3 months after the last dose.</p>

            <h5 class="primary">Adverse Reactions</h5>
            <ul>
                <li>
                    <p>The most common adverse reactions observed in more than 25% of patients with relapsed or refractory PTCL in the trial, who were treated with BELEODAQ, were nausea (42%), fatigue (37%), pyrexia (35%), anemia (32%), and vomiting (29%).</p>
                </li>
                <li>
                    <p>Sixty-one patients (47.3%) experienced serious adverse reactions while taking BELEODAQ or within 30 days after their last dose of BELEODAQ. The most common serious adverse reactions (>2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure.</p>
                </li>
            </ul>
            <h5 class="primary">Drug Interactions</h5>
            <ul>
                <li>
                    <p>BELEODAQ is primarily metabolized by UGT1A1. Avoid concomitant administration of BELEODAQ with strong inhibitors of UGT1A1.</p>
                </li>
            </ul>
            <h5 class="primary">Use in Specific Populations</h5>
            <p><span class="semibold">Lactation:</span> Due to the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with BELEODAQ and for 2 weeks after the last dose.</p>
            <p><span class="semibold">Pregnancy Testing:</span> BELEODAQ can cause fetal harm when administered to a pregnant woman. Pregnancy testing is recommended for females of reproductive potential prior to initiating BELEODAQ.</p>
            <p><span class="semibold">Pediatric Use:</span> The safety and effectiveness of BELEODAQ in pediatric patients have not been established.</p>
        </section>
    </footer>
    <!-- Vanilla JS -->
    <script src="js/app.js"></script>
</body>
</html>